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mismatched stem cell donor/recipient pairs expressed as a sequence similarity matching (SSM). SSM is based
on the structure of HLA molecules and the functional similarity of amino acids. According to this algorithm,
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1410 Biol Blood Marrow Transplant 17:1404-1415, 2011M. Askar et al.deleterious impact on stem cell transplant outcomes. We investigated the potential of SSM to predict high-
risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease (aGVHD
grades III and IV) published by Kawase et al., by comparing SSM in low- and high-risk combinations. SSM
was calculated for allele mismatch combinations using the HistoCheck tool available on the Web (www.his-
tocheck.org). We compared ranges and means of SSM among high-risk (15 combinations observed in 722
donor/recipient pairs) versus low-risk allele combinations (94 combinations in 3490 pairs). Simulation sce-
narios were created where the recipient’s HLA allele was involved in multiple allele mismatch combinations
with at least 1 high-risk and 1 low-risk mismatch combination. SSM values were then compared. The mean
SSM for high- versus low-risk combinations were 2.39 and 2.90 at A, 1.06 and 2.53 at B, 16.60 and 14.99 at C,
4.02 and 3.81 at DRB1, and 7.47 and 6.94 at DPB1 loci, respectively. In simulation scenarios, no predictable
SSM association with high- or low-risk combinations could be distinguished. NoDQB1 combinations met the
statistical criteria for our study. In conclusion, our analysis demonstrates that mean SSM scores were not
significantly different, and SSM distributions were overlapping among high- and low-risk allele combinations
within loci HLA-A, B, C, DRB1, and DPB1. This analysis does not support selecting donors for HSCTrecip-
ients based on low HistoCheck SSM scores.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative therapy for many hemato-
logic and nonhematologic disorders. The steady ex-
pansion of unrelated stem cell donor registries has
facilitated finding amatched donor formany transplant
candidates, particularly those with common human
leukocyte antigens (HLA) alleles and haplotypes.
However, the extensive polymorphism of HLA and
the remarkable disparity in the distribution of alleles
and haplotypes among individuals of different ethnic
and racial backgrounds remain a major hurdle for
access of many patients to HSCT. A number of studies
have shown that donor/recipientmatching for alleles at
HLA-A, -B, -C, -DRB1, and -DQB1 loci lowers the
risk of clinically severe acute graft-versus-host disease
(aGVHD) [1-3]. Recently, HLA-DPB1 allele mis-
matches were also significantly associated with an in-
creased incidence of GVHD [4-6]. When only HLA
mismatched donors are available for a given patient,
the challenge becomes determining which mismatch
has a less deleterious impact on clinical outcomes.
Bray and colleagues [7], in a comprehensive commen-
tary, described the National Marrow Donor Program
(NMDP) guidelines for unrelated HSC donor selec-
tion including the impact of mismatches at different
loci on HSCT clinical outcomes. In 2004, Elsner and
colleagues [8] proposed the HistoCheck Web-based
tool to estimate the allogenicity of mismatches with
a sequence similarity matching (SSM) concept. In this
concept, an SSM score (ie, allogenicity index) is gener-
ated by rating the amino acid (AA) differences between
HLA allelic products based on the position within the
HLA molecule and the functional similarity of AA
within proteins [9]. A high SSM score (also referred
to as Dissimilarity Score [DSS]) represents high dis-similaritybetweenHLAalleles resulting inapotentially
greater deleterious impact on clinical outcomes. How-
ever, this algorithm has been challenged by 2 single-
center analyses that could not associate higher SSM
scores with aGVHD (in 26 patients) or in vitro T cell
reactivity (in 74 patients) [10,11]. In the present
study, we investigated the potential of SSM scores to
predict high-risk HLA allele mismatch combinations
responsible for severe aGVHD (grades III and IV) ob-
served in a large cohort (5120 consecutive patients) of
HSCT donor/recipient pairs. These allele combina-
tions were observed in HSC transplants facilitated by
the Japan Marrow Donor Program (JMDP) and pub-
lished by Kawase et al. [12]. This investigation was
conducted by comparing SSM scores in high-risk and
low-risk allele combinations at HLA-A, -B, -C,
-DRB1, and -DPB1 loci. No high-risk allele combina-
tions at DQB1 locus met the predetermined level of
statistical significance (P\ .005) and thus SSM predic-
tions were not evaluated in this study.METHODS
Identification of High- and Low-Risk HLA Allele
Mismatch Combinations
Significant high-risk HLA allele mismatch combi-
nations were identified by retrospective analysis of
5210 consecutive registered patients who underwent
transplantation through the JMDP. Patient character-
istics, HLA matching and typing methods, and trans-
plant procedures are described elsewhere [12].
Briefly, 15 mismatch allele combinations were identi-
fied as high-risk allele mismatch combinations (4 at
HLA-A, 1 at HLA-B, 6 at HLA-C, 1 at HLA-DRB1,
and 2 at HLA-DPB1 loci). Only 1-allele mismatched
pairs in the same HLA locus were considered, and
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These mismatch combinations were found to be asso-
ciated with hish risk of severe aGVHD in a multivari-
able Cox regression model constructed with mismatch
combinations and potential confounders. Con-
founders considered were sex, patient age, donor age,
type of disease, risk of leukemia relapse, GVHD pro-
phylaxis, and preconditioning. Each HLA mismatch
combination was evaluated for each locus separately,
for example, in the A*02:06-A*02:01 allele mismatch
combination, the donor has HLA-A*02:06, recipient
has HLA-A*02:01, and the other HLA-A allele of
each donor and recipient was identical. This mismatch
was compared with the HLA-A allele match. An allele
mismatch combination was designated as a significant
high-risk combination for severe aGVHD based on P
values for hazard ratios (HR) for developing severe
aGVHD of\.005. For example, the above mismatch
combination was observed in 131 donor/recipient
pairs and was associated with increased hazard of se-
vere aGVHD (HR: 1.78, 95% confidence interval
[CI]: 1.32-2.41, P\ .001). Therefore, this was consid-
ered a high-risk mismatch allele combination. On the
other hand, allele mismatch combinations with
a 95% CI of the HR including 1.00 were considered
low-risk combinations. For example, the combination
A*24:02-A*24:20 was observed in 60 donor/recipient
pairs and was not associated with increased risk of se-
vere aGVHD (HR: 0.64, 95% CI: 0.32-1.30, P 5
.225). In addition, high-risk allele combinations
observed in the context of 2 loci-linked mismatches
such as (DRB1*14:03-DQB1*03:01) – (DRB1*14:01-
DQB1*05:02) were excluded from this analysis be-
cause there are no explicit provisions regarding the
utility of the HistoCheck algorithm in this setting.
SSM Score Calculation and Comparisons
SSM scores were calculated using the HistoCheck
tool available online at http://www.histocheck.org/
according to the instructions posted on that Website.
The averages and the distribution of SSM values
were compared among high- and low-risk allele mis-
match combinations in the same locus.
Simulation Scenarios
Hypothetical scenarios were created where the
recipient’s HLA allele was involved in multiple allele
mismatch combinations with at least 1 high-risk mis-
match and 1 low-risk mismatch. These scenarios
were created to simulate clinical scenarios where mul-
tiple mismatched donors are considered for a given re-
cipient in the absence of a matched donor. In these
instances, SSM scores were compared among donors
from both types of mismatch combinations. In addi-
tion, to investigate the impact of the direction of the al-
lele mismatch, we assessed whether any of theidentified 15 high-risk mismatch allele combinations
associated with severe aGVHD were also a high-risk
combination when considering the reverse direction
of the mismatch between donor and recipient. For ex-
ample, in the high-risk mismatch combination HLA-
A*26:01/26:02, the recipient had the HLA-A*26:02
allele and the donor had the HLA-A*26:01. In this in-
stance, we reviewed the list of the high- and low-risk
mismatch allele combinations from the Kawase study
to assess the risk associated with the reverse combina-
tion (ie, recipient is HLA-A*26:01 and donor is HLA-
A*26:02). The same assessment was performed for all
identified high-risk combinations.
Statistical Analysis
For the purpose of this analysis, low-risk mismatch
allele combinations were used as a control group for
SSM comparisons. SSM means and distributions were
compared among aggregates of low-risk mismatch al-
lele combinations and aggregates of high-risk combi-
nations as well as individual high-risk combinations.RESULTS
High- versus Low-Risk Allele Mismatch
Combinations
In theHLA-A locus, the 4 high-risk allelemismatch
combinations (observed 214 HSCT donor-recipient
pairs) had a mean SSM of 2.39 (range: 1.04-4.30) com-
pared to a mean SSM of 2.90 (range: 1.04-5.66) in 11
low-risk combinations (observed in 389 pairs). Individ-
ual high-risk combinations had the following SSM
values: 1.04 (A*02:06-02:01), 2.87 (A*02:06-02:07),
1.36 (A*26:02-26:01), and 4.3 (A*26:03-26:01).
The 1 high-risk combination (B*15:01-15:07, ob-
served in 19 pairs) at HLA-B locus had an SSM value
of 1.06. The mean SSM for 4 B low-risk combinations
was 2.53 (range: 1.74-2.81). In the HLA-C locus, the
mean SSM for the 7 high-risk combinations (observed
in 316 pairs) was 16.60 (range: 12.36-23.86) compared
to a mean SSM of 14.99 (range 1.52-23.86) in 18 low-
risk combinations (observed in 578 pairs). The 1 high-
risk combination (DRB1*04:05-04:03, observed in 53
pairs) at HLA-DRB1 locus had an SSM value of 4.02.
The mean SSM for 4 DRB1 low-risk combinations
was 3.81 (range: 1.30-10.41). Finally, at the HLA-
DPB1 locus, themeanSSMfor the 2high-risk combina-
tions (observed in 120 pairs) was 7.47 (range: 6.98-7.95)
compared to a mean SSM of 6.94 (range 1.21-12.87) in
36 low-risk combinations (observed in 1594 pairs).
A graphical representation of overall comparisons
of SSM means and distributions among aggregates of
low-risk mismatch allele combinations and aggregates
of high-risk combinations as well as individual high-
risk combinations across all loci is depicted in
Figure 1. Without exception, in all these loci, the SSM
Figure 1. Comparison of SSM in high- versus low-riskmismatch allele combinations. SSMmeans are not significantly different, and SSM distributions are
overlapping among high- and low-risk allele combinations within loci HLA-A, -B, -C, -DRB1, and -DPB1.
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low the range for the low-risk combinations. Two of
15 high-risk combinations had SSM scores that were
lower than or equal to the lowest SSM score in any of
the low-risk combinations in the corresponding locus.
A detailed list of individual low-risk combinations is pre-
sented in the original publication by Kawase et al. [12].Simulation Scenarios
To simulate clinical scenarios where multiple mis-
matched donors are considered for a given recipient,
SSM values for high-risk and low-risk combinations in-
cluding the same recipient allele were compared. The
recipient allele in 13 of the 15 identified high-risk mis-
match allele combinations (Loci HLA*A, C*, DRB1*,
and DPB1*) was included in 1 or more low-risk allele
mismatch combinations (Table 1). In1 scenario, a recip-
ient with an A*02:07 allele had 2 potential mismatched
donors at this allele for either A*02:06 (high-risk
mismatch allele combination) or A*02:01 (low-riskmis-
match allele combination). SSM values for the high-risk
and the low-risk combinations were 2.90 and 1.83, re-
spectively, as one might expect. However, in another
scenario, a recipient with an A*02:01 allele had 2 poten-
tial mismatched donors at this allele for either A*02:06
(high-risk mismatch allele combination) or A*02:07
(low-risk mismatch allele combination), the opposite
was observed. SSM values for the high- and the low-
risk combinations were 1.04 and 1.83, respectively. All
simulation scenarios are summarized in Table 1.
Overall, no predictable SSM pattern of associa-
tion with high- or low-risk mismatch allele combina-
tions could be distinguished. In all but 2 instances (at
HLA-A* and -DRB1* loci), at least 1 low-risk combi-
nation scored a higher SSM value than the high-riskmismatch combination including the same recipient
allele.
Direction of the Allele Mismatch Combinations
None of the 15 high-risk combinations were high
risk in both directions. In 10 of these combinations,
when the direction of the allele mismatch was reversed
between donor and recipient, there was no longer an
association with severe aGVHD (Table 2). An example
of such a unidirectional risk is the combination where
the recipient has A*02:01 and the donor has A*02:06
(high risk) versus the recipient having A*02:06 and
the donor having A*02:01(low risk). Both of these
combinations have an SSM value of 1.04 according
to HistoCheck.DISCUSSION
Optimal effectiveness and safety ofHSCT requires
high degree of HLA allele matching between donors
and recipients [7,13]. However, many patients who
need HSCT do not have an HLA-matched donor,
which lowers the probability of cure. Undoubtedly,
a predictive algorithm for definition of ‘‘low-risk’’
HLA mismatches has the potential of broadening the
use of mismatched donors and increasing the availabil-
ity of unrelated donors. Several approaches have been
proposed to identify such low-risk mismatches, with
the simplest being a comparison between alleles based
on the number of amino acid mismatches. However,
prior reports have not found any evidence for selecting
an allele with a lower number of AA substitutions of its
allelic product [14,15]. Although hypothetically
appealing, the notion that the lower the number of
AA substitutions the more low-risk the mismatch is
Table 1. Simulation Scenarios for Comparison between SSM Scores among Multiple High- versus Low-Risk Mismatched Donors
Potentially Available for a Patient with a Given HLA Allele
HLA Locus
MM Combination
(Donor-Patient) N HR (95% CI) P Risk Group SSM
A 02:06-02:01 131 1.78 (1.32-2.41) <.001 High 1.04
02:07-02:01 20 1.12 (0.42-3.02) .81 Low 1.83
02:06-02:07 27 3.45 (2.09-5.70) <.001 High 2.90*
02:01-02:07 28 0.83 (0.34-2.03) .70 Low 1.83
C 04:01-03:03 42 2.81 (1.72-4.60) .001 High 23.86
08:01-03:03 80 2.32 (1.58-3.40) .001 High 16.65
07:02-03:03 18 2.16 (0.96-4.85) .06 Low 21.90
03:04-03:03 62 0.83 (0.41-1.68) .61 Low 1.52
03:04-08:01 69 2.34 (1.55-3.52) .001 High 7.13
03:03-08:01 76 1.07 (0.63-1.84) .78 Low 16.65
14:02-03:04 23 3.66 (2.00-6.68) .001 High 17.30
15:02-03:04 27 3.77 (2.20-6.47) .001 High 12.36
08:01-03:04 47 1.64 (0.98-2.76) .06 Low 15.13
01:02-03:04 12 1.85 (0.59-5.81) .29 Low 18.30
07:02-03:04 33 1.22 (0.58-2.59) .59 Low 20.38
03:03-03:04 83 1.08 (0.63-1.85) .76 Low 1.52
03:03-15:02 25 3.22 (1.75-5.89) .001 High 13.88
08:01-15:02 36 1.59 (0.79-3.21) .19 Low 15.33
DRB1 04:05-04:03 53 2.13 (1.28-3.53) .003 High 4.02*
04:10-04:03 17 1.01 (0.32-3.21) .98 Low 2.50
04:06-04:03 30 0.99 (0.46-2.10) .99 Low 1.45
DPB1 05:01-09:01 71 2.03 (1.30-3.16) .002 High 7.95
04:02-09:01 17 0.33 (0.04-2.36) .27 Low 11.19
02:01-09:01 47 1.37 (0.75-2.51) .30 Low 9.98
03:01-09:01 15 0.8 (0.19-3.22) .75 Low 3.98
04:01-09:01 11 0.9 (0.22-3.66) .89 Low 12.87
03:01-05:01 49 2.41 (1.49-3.89) <.001 High 6.98
06:01-05:01 13 2.5 (0.92-6.77) .07 Low 7.95
04:02-05:01 79 1.47 (0.90-2.40) .12 Low 6.70
02:02-05:01 41 0.43 (0.13-1.35) .15 Low 6.18
09:01-05:01 48 0.71 (0.29-1.73) .46 Low 7.95
04:01-05:01 29 0.73 (0.23-2.29) .59 Low 5.46
14:01-05:01 26 1.17 (0.48-2.84) .73 Low 7.77
N indicates numberof donor-patient pairs inwhomthemismatchallele combinationwasobserved;HR, hazard ratioof developing severe acutt graft-versus-host
disease (aGVHD) compared to matched pairs as described in Kawase et al. [12]; SSM, sequence similarity matching; CI, confidence interval.
P values: for the corresponding estimated hazard ratio.
In all but 2 instances (marked with *), at least 1 low-risk combination scored a higher SSM value than the high-risk mismatch combination including the
same recipient allele.
*The only 2 instances where SSM value was highest for the combination associated severe aGVHD.
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NMDP registry analysis suggested no difference in
outcome when comparing antigen mismatch to allele
level (high resolution) mismatch within the same anti-
gen group [13]. Second, at least 2 reports have indi-
cated that severe aGVHD can occur in the presence
of only 1 AA mismatch between the donor and recipi-
ent allelic products [12,16].
In addition, at least 2 ‘‘epitope’’ based approaches
have been proposed. One is based on serologically
crossreactive groups (CREG) of antigens, and the other
is based on comparisons of ‘‘functional epitope’’ struc-
ture through molecular viewing of the HLA structure
and the determination of antibody-accessible polymor-
phic AAs (HLAMatchmaker) [17-19]. Neither of these
2 approaches have yielded predictions that were
associated with a survival benefit in patients who
underwent mismatched hematopoietic cell transplants
from unrelated donors in registry analyses [20,21].
In the current analysis, we investigated whether
HistoCheck SSM scores can predict 15 high-risk HLAallele mismatch combinations responsible for severe
aGVHD observed in 5120 consecutive HSCT donor-
recipient pairs facilitated through JMDP. It is note-
worthy that the association between these 15 allele
combinations and high risk for severe aGVHD has not
yet been validated in an independent patient popula-
tion; however, we believe that this association is rea-
sonably robust because of the conservative approach
and the rigorous statistical methods pursued in assign-
ing these associations as described elsewhere [12].
SSM score comparisons were performed between
high-risk and low-risk combinations at loci HLA-A,
-B, -C, -DRB1, and -DPB1. Significant overlap exists
between the high- and low-riskmismatcheswith respect
to SSMscores. In all investigated loci, the SSM score for
each high-risk combination fell within or below the
range for the low-risk combinations, thus demonstrat-
ing the unreliability of SSM scores with respect to
aGVHD risk. In addition, in 2 high-risk combinations
(13%), SSM scores were less than or equal to the lowest
SSM score in any of the low-risk combinations in the
Table 2. Mismatch Allele Combinations Where the Risk of aGVHD Depends on the Direction of the Mismatch
HLA Locus
MM Combination
(Donor-Patient) N HR (95% CI) P Risk Group SSM
A* 02:06-02:01 131 1.78 (1.32-2.41) <.001 High 1.04
02:01-02:06 138 1.23 (0.87-1.73) .223 Low
02:06-02:07 27 3.45 (2.09-5.70) <.001 High 2.87
02:07-02:06 22 0.71 (0.23-2.24) .571 Low
26:02-26:01 21 3.35 (1.89-5.91) <.001 High 1.36
26:01-26:02 24 0.64 (0.26-1.58) .34 Low
26:03-26:01 35 2.17 (1.29-3.64) .003 High 4.30
26:01-26:03 34 1.37 (0.73-2.57) .326 Low
C* 08:01-03:03 80 2.32 (1.58-3.40) .001 High 16.65
03:03-08:01 76 1.07 (0.63-1.84) .782 Low
03:04-08:01 69 2.34 (1.55-3.52) .001 High 15.13
08:01-03:04 47 1.64 (0.98-2.76) .057 Low
04:01-03:03 42 2.81 (1.72-4.60) .001 High 23.86
03:03-04:01 31 1.73 (0.89-3.36) .103 Low
DRB1* 04:05-04:03 53 2.13 (1.28-3.53) .003 High 4.02
04:03-04:05 54 1.27 (0.74-2.20) .379 Low
DPB1* 05:01-09:01 71 2.03 (1.30-3.16) .002 High 7.95
09:01-05:01 48 0.71 (0.29-1.73) .457 Low
03:01-05:01 49 2.41 (1.49-3.89) <.001 High 6.98
05:01-03:01 83 1.20 (0.75-1.94) .434 Low
N indicatesnumberof donor-patient pairs inwhomthemismatch allele combinationwasobserved;HR, hazard ratioof developing severe acute graft-versus-host
disease (aGVHD) compared to matched pairs as described in Kawase et al. [12]; SSM, sequence similarity matching; CI, confidence interval.
P values: for the corresponding estimated hazard ratio.
None of the 15 high-risk combinations were high risk in both directions. In 10 of these combinations, when the direction of the allele mismatch was
reversed between donor and recipient, there was no longer an association with severe aGVHD.
*The only 2 instances where SSM value was highest for the combination associated with severe aGVHD.
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scenarios were constructed for recipients included in
both high- and low-risk combinations, one would ex-
pect that high-risk mismatch combinations have higher
SSM values compared to low-risk combinations of the
same recipient allele. However, only 2 of the 15 high-
risk combinations (13%) had higher SSM scores than
alternative low-risk combinations potentially available
for a patient with alleles included in these combinations.
Interestingly, none of the identified 15 mismatch allele
combinations were associated with high-risk for severe
aGVHD in both directions. Ten of these combinations
were no longer associated with severe aGVHD when
the direction of the allele mismatch was reversed be-
tween the donor and the recipient. However, the SSM
score remains unchanged bcause HistoCheck does not
distinguish the direction of the allelemismatch between
donor and recipient.
The lack of association between SSM and clinical
data in our study may be attributed at least in part to
the limitations acknowledged by the developers of the
algorithm.Namely, underestimating the impact of sin-
gle AA mismatches, not accounting for clinical data
suggesting disproportionately larger impact of substi-
tutions at given positions, particularly position 116,
and assignment of positions based on crystallographic
data of HLA-A2 for class I and of HLA-DR1 for class
II alleles [8]. In addition, HistoCheck by design does
not account for the direction of the allele mismatch,
which has shown to be clinically significant [12].
Limitations of our study include relatively few
numbers of high-risk allele mismatch combinations,not including mismatch combinations at the HLA-
DQB1 locus, the potential for misclassification of
some mismatch combinations as low risk because of
relatively small number of subjects in subcategories,
and inclusion of patients only from 1 ethnic back-
ground. Nevertheless, these results and previous re-
ports do not support the utilization of HistoCheck
predictions in unrelated donor selection [10,11].
In conclusion, safely maximizing access to mis-
matchedHSCTunrelated donors requires a robust un-
derstanding of the rules that govern permissible HLA
mismatching, and a better understanding of HLA-
associated risks of GVHD. The lack of association be-
tween theHistoCheck predictions and all previously pro-
posed prediction algorithms and the observed clinical
outcomes strongly emphasizes the utmost importance
of clinical validation of any prediction algorithm prior
to its utilization in clinical patient care. Moving for-
ward, it is prudent in evaluating any prediction algo-
rithm to rely primarily on clinical correlations rather
than simply putative biological plausibility.ACKNOWLEDGMENTS
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